TY - JOUR T1 - Postoperative Pancreatic Fistula After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Update on Incidence, Risk Factors, Management, and Clinical Sequelae in 1,141 Patients JF - Anticancer Research JO - Anticancer Res SP - 5577 LP - 5584 DO - 10.21873/anticanres.15371 VL - 41 IS - 11 AU - AMER MATAR AU - THOMAS MEARES AU - OLIVER M. FISHER AU - CHAHAYA GAUCI AU - APOORVA RAO AU - MOHAMMAD ALSHAHRANI AU - NAYEF ALZAHRANI AU - DAVID L. MORRIS Y1 - 2021/11/01 UR - http://ar.iiarjournals.org/content/41/11/5577.abstract N2 - Background/Aim: An update on the incidence, risk factors, clinical sequalae, and management of postoperative pancreatic fistula (POPF) following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Patients and Methods: Retrospective analysis of prospectively collected data from the St George CRS/HIPEC database. Results: Sixty-five (5.7%) out of 1,141 patients developed a POPF. Patients with POPFs were older, had a higher peritoneal cancer index, longer operation time, and required more units of blood intraoperatively. Splenectomy and distal pancreatectomy were significant risk factors for developing POPFs. While there was no effect on overall long-term survival in POPF patients, they did suffer higher rates of Clavien–Dindo grade 3/4 complications, in-hospital deaths, and longer hospital length of stay. Of the 65 POPF patients, 23 were taken back to theatre, 48 required radiological drains and 7 underwent endoscopic retrograde cholangiopancreatography. Conclusion: There are multiple risk factors for developing POPFs that are non-modifiable. While POPFs are associated with increased postoperative morbidity, long-term survival does not appear to be affected. ER -